Sinphar Pharmaceutical (Taiwan) Performance
| 1734 Stock | TWD 30.85 0.25 0.82% |
The entity has a beta of 0.55, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sinphar Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sinphar Pharmaceutical is expected to be smaller as well. At this point, Sinphar Pharmaceutical has a negative expected return of -0.14%. Please make sure to validate Sinphar Pharmaceutical's jensen alpha, treynor ratio, and the relationship between the standard deviation and total risk alpha , to decide if Sinphar Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sinphar Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | -205.6 M |
Sinphar |
Sinphar Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 3,376 in Sinphar Pharmaceutical Co on September 2, 2024 and sell it today you would lose (291.00) from holding Sinphar Pharmaceutical Co or give up 8.62% of portfolio value over 90 days. Sinphar Pharmaceutical Co is generating negative expected returns and assumes 0.7097% volatility on return distribution over the 90 days horizon. Simply put, 6% of stocks are less volatile than Sinphar, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sinphar Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sinphar Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sinphar Pharmaceutical Co, and traders can use it to determine the average amount a Sinphar Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1948
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1734 |
Estimated Market Risk
| 0.71 actual daily | 6 94% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sinphar Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sinphar Pharmaceutical by adding Sinphar Pharmaceutical to a well-diversified portfolio.
Sinphar Pharmaceutical Fundamentals Growth
Sinphar Stock prices reflect investors' perceptions of the future prospects and financial health of Sinphar Pharmaceutical, and Sinphar Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sinphar Stock performance.
| Return On Equity | 0.0444 | |||
| Return On Asset | 0.0207 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 6.26 B | |||
| Shares Outstanding | 167.72 M | |||
| Price To Earning | 536.84 X | |||
| Price To Book | 1.88 X | |||
| Price To Sales | 2.15 X | |||
| Revenue | 2.43 B | |||
| EBITDA | 109.64 M | |||
| Cash And Equivalents | 937.43 M | |||
| Cash Per Share | 5.59 X | |||
| Total Debt | 1.49 B | |||
| Debt To Equity | 51.50 % | |||
| Book Value Per Share | 17.41 X | |||
| Cash Flow From Operations | 135.54 M | |||
| Earnings Per Share | 1.18 X | |||
| Total Asset | 6.22 B | |||
| Retained Earnings | 237 M | |||
| Current Asset | 2.28 B | |||
| Current Liabilities | 999 M | |||
About Sinphar Pharmaceutical Performance
Evaluating Sinphar Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sinphar Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sinphar Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. ,Ltd. was founded in 1977 and is headquartered in Yilan, Taiwan. SINPHAR PHARMACEUTICAL operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about Sinphar Pharmaceutical performance evaluation
Checking the ongoing alerts about Sinphar Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sinphar Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sinphar Pharmaceutical generated a negative expected return over the last 90 days | |
| The company reported the revenue of 2.43 B. Net Loss for the year was (38.13 M) with profit before overhead, payroll, taxes, and interest of 888.71 M. | |
| About 20.0% of the company shares are owned by insiders or employees |
- Analyzing Sinphar Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sinphar Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Sinphar Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sinphar Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sinphar Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sinphar Pharmaceutical's stock. These opinions can provide insight into Sinphar Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.